Celiac Disease Study Notes

Celiac Disease Overview

  • Celiac disease is a common cause of chronic diarrhea along with various gastrointestinal symptoms.

  • It is an immunologically mediated disorder of the small intestine triggered by dietary exposure to gluten-containing proteins found in wheat, barley, and rye.

  • The hallmark of celiac disease is villous atrophy, which often improves or resolves after the removal of these offending proteins from the diet.

Pathophysiology

  • Normal Small Bowel Appearance:

    • Shows prominent villi.

  • Celiac Disease Appearance:

    • Characterized by flattening of villi and increased inflammatory cell infiltrate in the intestinal mucosa.

  • Celiac disease can manifest with:

    • Gastrointestinal symptoms (e.g., diarrhea, malabsorption).

    • Systemic symptoms (e.g., fatigue).

Etiology

  • Celiac disease has a clear genetic predisposition compared to inflammatory bowel disease, though it is also multifactorial involving both environmental and immunological factors.

  • Key Proteins Involved:

    • Gliadins in wheat.

    • Hordines in barley.

    • Secalins in rye.

    • Collectively referred to as gluten, these proteins are rich in glutamines and prolines and are incompletely digested by gastric, pancreatic, and brush border proteases.

  • Post-digestion, large peptides may enter the lamina propria (either transcellularly or paracellularly), eliciting an immune response in genetically susceptible individuals, as the peptides are perceived as foreign proteins.

Genetic Factors

  • Genetic predisposition to celiac disease shows significant familial clustering:

    • First-degree relatives: 5-10% risk of developing celiac disease.

    • HLA identical siblings: ~30% risk.

    • Identical twins: >75% risk.

  • HLA Haplotypes:

    • Presence of HLA-DQ2 or HLA-DQ8 is necessary but not sufficient for celiac disease development.

    • These haplotypes allow for the potential development of celiac disease, but their presence does not guarantee its occurrence.

    • Around 30% of the general population can be HLA-DQ2/DQ8 positive without having celiac disease.

    • HLA-DQ testing is not diagnostic for celiac disease but can exclude it in negative test results.

Environmental Factors

  • There are no clear relationships between the age of gluten introduction, breastfeeding, or factors like smoking and antibiotic use with the development of celiac disease.

  • The role of the gut microbiome in celiac disease development remains questionable.

Immune Response Mechanism

  • Tissue Transglutaminase (tTG): A critical component in the immune response of celiac disease. It:

    • Is found in gut mucosa and functions as a repair enzyme.

    • Deamidates glutamine in gliadin to glutamate, increasing the gliadin's affinity for HLA-DQ2/DQ8 antigen-presenting cells.

  • The gliadin-tTG complex is then presented to CD4 T cells, instigating a harmful immune response resulting in:

    • Tissue damage.

    • Villous atrophy.

  • Consequences of Villous Atrophy:

    • Decreased absorptive capacity, leading to malabsorption and diarrhea.

Epidemiology

  • Celiac disease affects approximately 1% of the population.

  • It is more prevalent in individuals of Northern European ancestry and rare in certain ethnic groups, such as ethnic Chinese.

  • The diagnosis rate is increasing, possibly due to better awareness, improved testing, or real changes in incidence.

  • There’s often a diagnostic delay of 5-10 years, with many cases remaining undetected (termed silent celiac disease).

Clinical Spectrum of Celiac Disease

  • The clinical spectrum includes:

    • Potential Celiac Disease: Positive serological tests, normal intestinal biopsies.

    • Asymptomatic Patients: Positive serology and histological changes without symptoms.

    • Symptomatic Patients: Present with diarrhea and malabsorption symptoms, possibly leading to anemia and osteoporosis.

    • Refractory Celiac Disease: Persistent symptoms and villous atrophy despite adherence to a strict gluten-free diet.

Associated Conditions and Symptoms

  • Increased frequency of autoimmunity in patients with celiac disease includes:

    • Autoimmune thyroiditis

    • Atrophic gastritis

    • Type 1 diabetes

    • Primary biliary cholangitis

    • Autoimmune hepatitis

  • Other manifestations include:

    • Dermatitis Herpetiformis: Itchy rash on upper limbs.

    • IgA Deficiency: Common among individuals with celiac disease.

    • Osteoporosis: 20-40% of untreated patients are osteopenic; bone mineral density decreases with age at diagnosis.

Diagnosis of Celiac Disease

  • Diagnostic Process:

    • Includes serological antibody testing and small bowel biopsy.

    • HLA testing supports diagnosis but is not solely diagnostic.

    • Testing must occur while the patient is still consuming gluten.

  • Key Antibodies Tested:

    • Anti-gliadin Antibody (especially deamidated).

    • Anti-endomysial Antibody.

    • Anti-tissue Transglutaminase Antibody: Most prevalent and commonly used.

    • IgA and IgG testing is also crucial due to co-existing IgA deficiencies.

  • Endoscopic Findings:

    • Normal appearance of the duodenum contrasts sharply with celiac disease, which shows loss of small bowel Hausdorff features, blunting of folds, and mucosal denudation.

    • Histological changes include villous atrophy and intraepithelial lymphocytosis.

HLA Testing and Its Implications

  • HLA-DQ2/DQ8 testing:

    • Essential but not sufficient for diagnosis.

    • Positive results are less helpful; negative results can exclude celiac disease.

  • Indications for HLA testing include:

    • Diagnostic uncertainty with negative or low antibody positivity.

    • Patients on gluten-free diets seeking to exclude celiac disease without gluten challenge.

Treatment

  • Treatment:

    • A strict lifelong gluten-free diet (excludes wheat, barley, rye, and possibly oats).

    • Importance of compliance to avoid symptoms and complications.

    • Risk management for potential surreptitious gluten ingestion from processed foods or shared food preparations.

  • Rationale for Treatment:

    • Relief of symptoms and improvement in quality of life.

    • Prevention of malabsorption-related conditions (e.g., anemia, osteoporosis).

    • Mitigation of cancer risk associated with untreated celiac disease, including lymphoma and small bowel adenocarcinoma.

Monitoring and Follow-Up

  • Follow-up strategies include:

    • Periodic blood tests (every 6 months) to monitor antibody titers for normalization.

    • Repeat gastroscopy (6-12 months) to assess mucosal recovery and confirm resolution of histological changes.

    • Monitoring of nutritional markers, including iron studies and periodic bone mineral density assessments.

  • Nonresponsive Celiac Disease:

    • Many patients remain nonresponsive due to either intentional or unintentional gluten ingestion.

    • Other conditions contributing to nonresponsiveness include ulcerative jejunoileitis and refractory sprue.

Conclusion

  • Awareness and suspicion for celiac disease are critical, given its prevalence and often nonspecific presentation.

  • Diagnostic confirmation requires small bowel biopsy, while antibody testing provides essential supporting evidence.

  • HLA testing is useful but not definitive; it has a strong negative predictive value for disease exclusion.

  • Key management strategy includes adherence to a gluten-free diet, which is crucial for symptom resolution and preventing complications.